Molecular Medicine Partnership Unit

Last updated

The Molecular Medicine Partnership Unit is an alliance between the European Molecular Biology Laboratory and the Medical Faculty of the University of Heidelberg. Its primary aim is to uncover the molecular basis of disease and to speed the transformation of biomedical discoveries into personalized medicine strategies.

Contents

Founded in 2002, the Molecular Medicine Partnership Unit (MMPU) comprises ten inter-disciplinary research teams. It is co-directed by Prof. Andreas Kulozik from the Angelika-Lautenschläger Hospital for Children and Adolescents at the University of Heidelberg, by Prof. Matthias Hentze and Dr. Wolfgang Huber (scientist) from the European Molecular Biology Laboratory, and is housed in the Otto-Meyerhof-Research Center on the Medical Campus of the University of Heidelberg, Germany.

European Molecular Biology Laboratory campus in Heidelberg. Photo: Photolab EMBL EMBL campus Heidelberg.jpg
European Molecular Biology Laboratory campus in Heidelberg. Photo: Photolab EMBL
Otto-Meyerhof-Research Center in Heidelberg. Photo: Medienzentrum Universitatsklinikum Heidelberg OMZ Heidelberg.jpg
Otto-Meyerhof-Research Center in Heidelberg. Photo: Medienzentrum Universitätsklinikum Heidelberg

Research themes

Research themes place emphasis on common diseases as well as on rare diseases with a particular medical need.

In 2024 more than 120 international scientists work on the following ten research themes:

Selected recent publications

Related Research Articles

<span class="mw-page-title-main">SARS-related coronavirus</span> Species of coronavirus causing SARS and COVID-19

Severe-acute-respiratory-syndrome–related coronavirus is a species of virus consisting of many known strains. Two strains of the virus have caused outbreaks of severe respiratory diseases in humans: severe acute respiratory syndrome coronavirus 1, which caused the 2002–2004 outbreak of severe acute respiratory syndrome (SARS), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is causing the ongoing pandemic of COVID-19. There are hundreds of other strains of SARSr-CoV, which are only known to infect non-human mammal species: bats are a major reservoir of many strains of SARSr-CoV; several strains have been identified in Himalayan palm civets, which were likely ancestors of SARS-CoV-1.

Polyadenylation is the addition of a poly(A) tail to an RNA transcript, typically a messenger RNA (mRNA). The poly(A) tail consists of multiple adenosine monophosphates; in other words, it is a stretch of RNA that has only adenine bases. In eukaryotes, polyadenylation is part of the process that produces mature mRNA for translation. In many bacteria, the poly(A) tail promotes degradation of the mRNA. It, therefore, forms part of the larger process of gene expression.

<span class="mw-page-title-main">European Molecular Biology Laboratory</span> Molecular biology research institution

The European Molecular Biology Laboratory (EMBL) is an intergovernmental organization dedicated to molecular biology research and is supported by 29 member states, one prospect member state, and one associate member state. EMBL was created in 1974 and is funded by public research money from its member states. Research at EMBL is conducted by more than 110 independent research groups and service teams covering the spectrum of molecular biology.

<span class="mw-page-title-main">Patrick Cramer</span> German biochemist (born 1969)

Patrick Cramer is a German chemist, structural biologist, and molecular systems biologist. In 2020, he was honoured to be an international member of the National Academy of Sciences. He became president of the Max Planck Society in June 2023.

The Structural Genomics Consortium (SGC) is a public-private-partnership focusing on elucidating the functions and disease relevance of all proteins encoded by the human genome, with an emphasis on those that are relatively understudied. The SGC places all its research output into the public domain without restriction and does not file for patents and continues to promote open science. Two recent publications revisit the case for open science. Founded in 2003, and modelled after the Single Nucleotide Polymorphism Database (dbSNP) Consortium, the SGC is a charitable company whose Members comprise organizations that contribute over $5,4M Euros to the SGC over a five-year period. The Board has one representative from each Member and an independent Chair, who serves one 5-year term. The current Chair is Anke Müller-Fahrnow (Germany), and previous Chairs have been Michael Morgan (U.K.), Wayne Hendrickson (U.S.A.), Markus Gruetter (Switzerland) and Tetsuyuki Maruyama (Japan). The founding and current CEO is Aled Edwards (Canada). The founding Members of the SGC Company were the Canadian Institutes of Health Research, Genome Canada, the Ontario Research Fund, GlaxoSmithKline and Wellcome Trust. The current Members comprise Bayer Pharma AG, Bristol Myers Squibb, Boehringer Ingelheim, the Eshelman Institute for Innovation, Genentech, Genome Canada, Janssen, Merck KGaA, Pfizer, and Takeda.

<span class="mw-page-title-main">Iron response element</span>

In molecular biology, the iron response element or iron-responsive element (IRE) is a short conserved stem-loop which is bound by iron response proteins. The IRE is found in UTRs of various mRNAs whose products are involved in iron metabolism. For example, the mRNA of ferritin contains one IRE in its 5' UTR. When iron concentration is low, IRPs bind the IRE in the ferritin mRNA and cause reduced translation rates. In contrast, binding to multiple IREs in the 3' UTR of the transferrin receptor leads to increased mRNA stability.

<span class="mw-page-title-main">UPF2</span> Protein-coding gene in the species Homo sapiens

Regulator of nonsense transcripts 2 is a protein that in humans is encoded by the UPF2 gene.

<span class="mw-page-title-main">UPF3B</span> Protein-coding gene in the species Homo sapiens

Regulator of nonsense transcripts 3B is a protein that in humans is encoded by the UPF3B gene.

<span class="mw-page-title-main">Matthias Hentze</span> German scientist

Matthias Werner Hentze is a German scientist. He is the director of the European Molecular Biology Laboratory (EMBL), co-director of the Molecular Medicine Partnership Unit between EMBL and Heidelberg University, and Professor of Molecular Medicine at Heidelberg University.

<span class="mw-page-title-main">Giulio Superti-Furga</span> Italian molecular and systems biologist

Giulio Superti-Furga is an Italian molecular and systems biologist based in Vienna, Austria. He is the Scientific Director of CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, and Professor of Medical Systems Biology at the Medical University of Vienna. In January 2024, he was appointed Chair of EU-LIFE, the alliance of research institutes advocating for excellent research in Europe.

<span class="mw-page-title-main">RNA interference</span> Biological process of gene regulation

RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. Historically, RNAi was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The detailed study of each of these seemingly different processes elucidated that the identity of these phenomena were all actually RNAi. Andrew Fire and Craig C. Mello shared the 2006 Nobel Prize in Physiology or Medicine for their work on RNAi in the nematode worm Caenorhabditis elegans, which they published in 1998. Since the discovery of RNAi and its regulatory potentials, it has become evident that RNAi has immense potential in suppression of desired genes. RNAi is now known as precise, efficient, stable and better than antisense therapy for gene suppression. Antisense RNA produced intracellularly by an expression vector may be developed and find utility as novel therapeutic agents.

<span class="mw-page-title-main">ChEMBL</span> Chemical database of bioactive molecules also having drug-like properties

ChEMBL or ChEMBLdb is a manually curated chemical database of bioactive molecules with drug inducing properties. It is maintained by the European Bioinformatics Institute (EBI), of the European Molecular Biology Laboratory (EMBL), based at the Wellcome Trust Genome Campus, Hinxton, UK.

<span class="mw-page-title-main">Paul Schimmel</span> American chemist

Paul Reinhard Schimmel is an American biophysical chemist and translational medicine pioneer.

Elisa Izaurralde was an Uruguayan biochemist and molecular biologist. She served as Director and Scientific Member of the Department of Biochemistry at the Max Planck Institute for Developmental Biology in Tübingen from 2005 until her death in 2018. In 2008, she was awarded the Gottfried Wilhelm Leibniz Prize, shared with Elena Conti, for "fundamental new insights into intracellular RNA transport and RNA metabolism". Together with Conti, she helped characterize proteins important for exporting mRNA out of the nucleus and later in her career she helped elucidate mechanisms of mRNA silencing, translational repression, and mRNA decay.

<span class="mw-page-title-main">CRISPR gene editing</span> Gene editing method

CRISPR gene editing standing for "Clustered Regularly Interspaced Short Palindromic Repeats" is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified. It is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defense system. By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added in vivo.

Asifa Akhtar is a Pakistani biologist who has made significant contributions to the field of chromosome regulation. She is Senior Group Leader and Director of the Department of Chromatin Regulation at the Max Planck Institute of Immunobiology and Epigenetics. Akhtar was awarded EMBO membership in 2013. She became the first international and female Vice President of the Max Planck Society's Biology and Medicine Section in July 2020.

Julius Brennecke is a German molecular biologist and geneticist. He is a Senior Group Leader at the Institute of Molecular Biotechnology. (IMBA) of the Austrian Academy of Sciences in Vienna.

Anne Ephrussi is a French developmental and molecular biologist. Her research is focused on the study of post-transcriptional regulations such as mRNA localization and translation control in molecular biology as well as the establishment of polarity axes in cell and developmental biology. She is director of the EMBL International Centre for Advanced Training (EICAT) program at the European Molecular Biology Laboratory (EMBL) since 2005 and served as head of the Developmental Biology Unit from 2007 to 2021.

A nucleoside-modified messenger RNA (modRNA) is a synthetic messenger RNA (mRNA) in which some nucleosides are replaced by other naturally modified nucleosides or by synthetic nucleoside analogues. modRNA is used to induce the production of a desired protein in certain cells. An important application is the development of mRNA vaccines, of which the first authorized were COVID-19 vaccines.

<span class="mw-page-title-main">Riccardo Cortese</span> Italian scientist and entrepreneur

Riccardo Cortese was an Italian scientist, entrepreneur, and innovator in the field of gene expression, drug discovery and genetic vaccines. His work led to the development of novel therapeutic strategies for the prevention and cure of viral infections, including HIV, HCV, Ebola and RSV. He pioneered a novel platform technology based on simian adenoviral vectors for prophylactic and therapeutic vaccines, and authored more than 300 publications in peer-reviewed journals in the field of gene expression, transcriptional control, molecular virology and immunology.

References